A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
The user experienced significant hair regrowth by returning to a regimen of 1mg oral finasteride daily and daily topical minoxidil after previously reducing their doses. They also emphasize maintaining energy and health through diet, exercise, and supplements.
The conversation is about finding high-purity RU58841 solutions for hair loss treatment, with mentions of Anagenic, Selleckchem, MV Supplement, and rudirect.co.uk as potential sources. Users discuss their experiences and preferences regarding product quality and shipping.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.
The user regrew their hairline using mechanical stimulation, including a 1.5mm derma roller weekly, daily scalp massages, and other treatments like Nizoral, zinc pyrithione, fish oil, and Lipogaine The Big 5. They did not use Minoxidil or finasteride.
The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.
The user experienced noticeable hairline regrowth after starting finasteride for crown hair loss, despite scalp irritation from topical minoxidil. They are impatient for crown results.
A 31-year-old male shared his 3-year progress using finasteride 1 mg daily, with additional treatments including nutrafol, multivitamins, vitamin D, marine collagen, PRP scalp injections, micro-needling, and Nizoral. He experienced temporary libido issues but currently has no side effects.
A user shared their progress using 1.1mg oral finasteride and 3mg oral minoxidil since January 2024, noting significant improvement without side effects. They previously had an allergic reaction to topical treatments.
A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.
Finasteride effectively regrew hair and improved quality after increasing the dose from 0.5mg to 1mg, with no side effects. The user is cautious about adding minoxidil, fearing it might disrupt progress.
The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.
The user is experiencing increased hair shedding while using finasteride and RU58841, possibly due to changes in application methods. They are considering adding minoxidil and stemoxydine to their regimen to improve results and manage hair greasiness.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
The user tried various hair loss treatments, including Maxogen-X, Dualgen15, minoxidil, finasteride, and dermarolling, but experienced limited regrowth and some side effects. They eventually switched to oral minoxidil, hoping for better results.
The user has been using topical finasteride since October without improvement and is considering adding a caffeine product with dimethylglycine. Another user suggests caffeine is more promising and advises consulting a dermatologist about the lack of progress with finasteride.
The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
GHK-CU is not considered as effective for hair loss as finasteride, minoxidil, or RU58841, with many users reporting minimal benefits. Some users experienced skin improvements, but its impact on hair is debated and often attributed to concurrent use of other treatments.
GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.
GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.
User taking 1mg finasteride daily for 2 years, wants to block more scalp DHT. Seeks reference for additional topical DHT blockers like alfatradiol and fluridil.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
The user experienced hair regrowth after one year on 1mg finasteride daily and a hair transplant in the frontal area, with improved density in the rear and mid-scalp. Some replies express skepticism and suggest the title should include mention of the hair transplant.
Finasteride is effective for treating male pattern baldness (MPB) with minimal side effects, and topical finasteride is similarly effective. Dutasteride is also effective but less understood, and Minoxidil is less effective than Finasteride.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.
OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.